HK1254083A1 - 用於治療癌症的缺氧活化前驅藥物和抗血管生成劑 - Google Patents

用於治療癌症的缺氧活化前驅藥物和抗血管生成劑

Info

Publication number
HK1254083A1
HK1254083A1 HK18113147.5A HK18113147A HK1254083A1 HK 1254083 A1 HK1254083 A1 HK 1254083A1 HK 18113147 A HK18113147 A HK 18113147A HK 1254083 A1 HK1254083 A1 HK 1254083A1
Authority
HK
Hong Kong
Prior art keywords
cancer
administration
treatment
antiangiogenic agents
hypoxia activated
Prior art date
Application number
HK18113147.5A
Other languages
English (en)
Inventor
Stewart Kroll
John Curd
Charles Hart
Jessica Sun
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of HK1254083A1 publication Critical patent/HK1254083A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18113147.5A 2010-07-12 2018-10-15 用於治療癌症的缺氧活化前驅藥物和抗血管生成劑 HK1254083A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36361010P 2010-07-12 2010-07-12
US201161470412P 2011-03-31 2011-03-31
US201161470812P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
HK1254083A1 true HK1254083A1 (zh) 2019-07-12

Family

ID=45470020

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113147.5A HK1254083A1 (zh) 2010-07-12 2018-10-15 用於治療癌症的缺氧活化前驅藥物和抗血管生成劑

Country Status (11)

Country Link
US (2) US20140010805A1 (zh)
EP (2) EP3311835B1 (zh)
JP (1) JP6066421B2 (zh)
KR (1) KR20130045341A (zh)
CA (1) CA2803675A1 (zh)
ES (2) ES2877629T3 (zh)
HK (1) HK1254083A1 (zh)
MX (1) MX2012014428A (zh)
RU (1) RU2597844C2 (zh)
WO (1) WO2012009288A2 (zh)
ZA (1) ZA201300692B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1896040T3 (pl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals Inc Proleki alkilatora fosforoamidowego
RU2473565C2 (ru) 2006-04-07 2013-01-27 Аерпио Терапетикс, Инк. АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ТИРОЗИН ФОСФАТАЗУ БЕТА ЧЕЛОВЕКА (HPTPβ), И ИХ ИСПОЛЬЗОВАНИЕ
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
JP5536113B2 (ja) 2009-07-06 2014-07-02 アケビア セラピューティクス インコーポレイテッド がん細胞の転移を予防するための化合物、組成物および方法
EP2694062A4 (en) 2011-04-01 2014-11-12 Threshold Pharmaceuticals Inc METHOD FOR THE TREATMENT OF CANCER
EP2696858A4 (en) * 2011-04-15 2014-09-03 Threshold Pharmaceuticals Inc UNIT DOSE FOR ORAL ADMINISTRATION
JP2014530244A (ja) 2011-10-13 2014-11-17 エアピオ セラピューティックス， インコーポレイテッド 血管漏出症候群および癌を治療する方法
US20150005262A1 (en) * 2011-12-22 2015-01-01 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs and mtor inhibitors for treating cancer
JP2015500885A (ja) 2011-12-22 2015-01-08 スレッショルド ファーマシューティカルズ，インコーポレイテッド 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
WO2013116385A1 (en) * 2012-01-31 2013-08-08 Threshold Pharmaceuticals, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
WO2013126539A1 (en) * 2012-02-21 2013-08-29 Threshold Pharmaceuticals Inc. Treatment of cancer
AU2015264805B2 (en) * 2012-06-01 2017-04-13 Bionomics Limited Combination Therapy
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2014062856A1 (en) * 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2014069063A1 (ja) 2012-10-29 2014-05-08 京セラ株式会社 弾性表面波センサ
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP2016519107A (ja) * 2013-04-10 2016-06-30 スレッショルド ファーマシューティカルズ，インコーポレイテッド Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー
WO2015013448A1 (en) 2013-07-26 2015-01-29 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
EP3164122A4 (en) * 2014-07-02 2018-02-28 Bionomics Limited Predicting response to cancer therapy
WO2016011195A1 (en) 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
WO2016014390A1 (en) * 2014-07-25 2016-01-28 Merck Patent Gmbh Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
KR102189066B1 (ko) * 2015-03-10 2020-12-09 아센타위츠 파마슈티컬즈 리미티드 Dna 알킬화제
US10829437B2 (en) 2015-04-02 2020-11-10 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
AU2016282785A1 (en) 2015-06-24 2018-02-15 Immunogenesis, Inc. Aziridine containing DNA alkylating agents
WO2017053566A1 (en) 2015-09-23 2017-03-30 Aerpio Therapeutics, Inc. Methods of treating intraocular pressure with activators of tie-2
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
CN118076359A (zh) 2021-08-27 2024-05-24 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
NZ521851A (en) 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
EP1680394A4 (en) 2003-10-31 2006-10-11 Auckland Uniservices Ltd NOVEL NITROPHENYL MUSTARD AND NOVEL NITROPHENYLAZIRIDINE ALCOHOLS, CORRESPONDING PHOSPHATES AND USE THEREOF AS TARGET CYTOTOXIC AGENTS
CN102641503A (zh) * 2004-07-20 2012-08-22 健泰科生物技术公司 血管生成素样4蛋白抑制剂，组合，以及其用途
PL1896040T3 (pl) * 2005-06-29 2012-12-31 Threshold Pharmaceuticals Inc Proleki alkilatora fosforoamidowego
JP2009510165A (ja) 2005-10-03 2009-03-12 ジェネティックス ファーマシューティカルズ， インク． 低酸素細胞を選択的に枯渇させるための方法
WO2008033041A1 (en) * 2006-09-11 2008-03-20 Auckland Uniservices Limited Cancer treatment
ES2884044T3 (es) * 2006-12-26 2021-12-10 Immunogenesis Inc Profármaco alquilante de fosforamidato para el tratamiento del cáncer
CN102026634B (zh) * 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
CA2724231A1 (en) * 2008-05-15 2009-11-19 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
ES2884674T3 (es) 2008-10-21 2021-12-10 Immunogenesis Inc Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed

Also Published As

Publication number Publication date
WO2012009288A9 (en) 2012-04-19
EP2593139A2 (en) 2013-05-22
WO2012009288A2 (en) 2012-01-19
KR20130045341A (ko) 2013-05-03
EP3311835B1 (en) 2021-03-24
RU2013103027A (ru) 2014-08-20
US20140010805A1 (en) 2014-01-09
MX2012014428A (es) 2013-03-05
EP2593139A4 (en) 2013-11-27
JP6066421B2 (ja) 2017-01-25
ES2649340T3 (es) 2018-01-11
ES2877629T3 (es) 2021-11-17
CA2803675A1 (en) 2012-01-19
ZA201300692B (en) 2013-09-25
EP3311835A1 (en) 2018-04-25
JP2013531038A (ja) 2013-08-01
US20190060275A1 (en) 2019-02-28
RU2597844C2 (ru) 2016-09-20
EP2593139B1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
HK1254083A1 (zh) 用於治療癌症的缺氧活化前驅藥物和抗血管生成劑
EP2740793A4 (en) MEDICINAL PREPARATION FOR CANCER TREATMENT AND / OR PREVENTION
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
IL225471B (en) Preparations for the prevention and treatment of cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
EP2532680A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
PT2532367T (pt) Agente farmacêutico para o tratamento e/ou prevenção do cancro
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL251083B (en) Compounds and preparations for the treatment of cancer
EP2558085A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
ZA201300762B (en) Novel combination therapy for the treatment of cancer
HK1201730A1 (zh) 抗癌劑的副作用的預防劑和/或治療劑
IL275636A (en) Medical combination for cancer treatment
EP2661434A4 (en) NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
IL223219A0 (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
GB201100404D0 (en) Combination of metformin and syrosingopine for the treatment of cancer and immunosuppression